A comparison of outcome of surgical treatment of migraine headaches using a constellation of symptoms versus botulinum toxin type a to identify the trigger sites

Plastic and Reconstructive Surgery

Volumn 129, Issue 2, 2012, Pages 413-419

  Liu, Mengyuan T ^a   Armijo, Bryan S ^a   Guyuron, Bahman ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; DIAGNOSTIC AGENT; MUSCLE RELAXANT AGENT;

ARTICLE; COMPARATIVE STUDY; HUMAN; INJECTION; METHODOLOGY; MIGRAINE; PREOPERATIVE CARE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TRIGGER POINT;

BOTULINUM TOXINS, TYPE A; HUMANS; INJECTIONS; MIGRAINE DISORDERS; NEUROMUSCULAR AGENTS; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIGGER POINTS;

EID: 84856707404     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e31823aecb7     Document Type: Article

References (26)

1. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-349.
2. SynerMed Communications. 21st century prevention and management of migraine headaches. Clin Courier 2001;19: 1-15.
3. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001; 41:646-657.
4. Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence: A review of population-based studies. Neurology 1994; 44(Suppl 4):S17-S23.
5. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol. 1984;16:157-168.
6. Goldberg LD. The cost of migraine and its treatment. Am J Manag Care 2005;11(Suppl 2):S62-S67.
7. Guyuron B, Kriegler JS, Davis J, Amini SB. Five-year outcome of surgical treatment of migraine headaches. Plast Reconstr Surg. 2010;127:603-608.
8. Guyuron B, Reed D, Kriegler JS, Davis J, Pashmini N, Amini S. A placebo controlled surgical trial for the treatment of migraine headaches. Plast Reconstr Surg. 2009;124:461-468.
9. Poggi JT, Grizzell BE, Helmer SD. Confirmation of surgical decompression to relieve migraine headaches. Plast Reconstr Surg. 2008;122:115-122; discussion 123-124.
10. Behin F, Behin B, Behin D, Baredes S. Surgical management of contact point headaches. Headache 2005;45:204-210.
11. Guyuron B. Botulinum toxin. Plastic Surgery: Indications, Operations, and Outcomes. St. Louis: Mosby; 2000.
12. Fenstermacher N, Levin M, Ward T. Pharmacological prevention of migraine. BMJ. 2011;342:d583.
13. Guyuron B, Kriegler JS, Davis J, Amini SB. Comprehensive surgical treatment of migraine headaches. Plast Reconstr Surg. 2005;115:1-9.
14. Janis JE, Ghavami A, Lemmon JA, Leedy JE, Guyuron B. Anatomy of the corrugator supercilii muscle: Part I. Corrugator topography. Plast Reconstr Surg. 2007;120:1647-1653.
15. Dirnberger F, Becker K. Surgical treatment of migraine headaches by corrugator muscle resection. Plast Reconstr Surg. 2004;114:652-657; discussion 658-659.
16. Totonchi A, Pashmini N, Guyuron B. The zygomaticotemporal branch of the trigeminal nerve: An anatomical study. Plast Reconstr Surg. 2005;115:273-277.
17. Mosser SW, Guyuron B, Janis JE, Rohrich RJ. The anatomy of the greater occipital nerve: Implications for the etiology of migraine headaches. Plast Reconstr Surg. 2004;113:693-697; discussion 698-700.
18. Dash K, Janis J, Guyuron B. The lesser and third occipital nerves and migraine headaches. Plast Reconstr Surg. 2005; 115:1752-1758; discussion 1759-1760.
19. Guyuron B, Becker DB. Surgical management of migraine headaches. In: Guyuron B, Eriksson E, Persing JA, et al., eds. Plastic Surgery: Indications and Practice. New York: Elsevier; 2009.
20. Guyuron B, DiNardo LA. Forehead/brow/soft tissue surgery for migraines. In: Evans G, Persing L, eds. Soft-Tissue Surgery of the Craniofacial Region. New York: Informa Healthcare USA; 2007:93-112.
21. Sultaneh A. Migraine: New surgical treatment. Paper presented at: Congress of Neurological Surgeons; September 29-October 4, 2001; San Diego, Calif.
22. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type A following longterm use. Eur J Neurol. 2006;13(Suppl 4):35-40.
23. Dressler D, Wohlfahrt K, Meyer-Rogge E, Wiest L, Bigalke H. Antibody-induced failure of botulinum toxin a therapy in cosmetic indications. Dermatol Surg. 2010;36(Suppl 4):2182-2187.
24. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003;60:1186-1188.
25. Klein AW. Complications and adverse reactions with the use of botulinum toxin. Dis Mon. 2002;48:336-356.
26. Schnider TW, Gaeta R, Brose W, Minto CF, Gregg KM, Shafer SL. Derivation and cross-validation of pharmacokinetic parameters for computer-controlled infusion of lidocaine in pain therapy. Anesthesiology 1996;84:1043-1050.